These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 717399)

  • 1. Circulating inhibitors of blood coagulation associated with procainamide-induced lupus erythematosus.
    Davis S; Furie BC; Griffin JH; Furie B; Willey R
    Am J Hematol; 1978; 4(4):401-7. PubMed ID: 717399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on a circulating anticoagulant in procainamide-induced lupus erythematosus.
    Edwards RL; Rick ME; Wakem CJ
    Arch Intern Med; 1981 Nov; 141(12):1688-90. PubMed ID: 6171218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The varied sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of the lupus-like anticoagulant.
    Mannucci PM; Canciani MT; Mari D; Meucci P
    Scand J Haematol; 1979 May; 22(5):423-32. PubMed ID: 472662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation Testing in the Core Laboratory.
    Winter WE; Flax SD; Harris NS
    Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procainamide-induced circulating anticoagulants in a congenitally-deficient factor XI patient.
    Clyne LP; Farber LR; Chopyk RL
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(2):239-44. PubMed ID: 2475403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on a circulating anticoagulant in systemic lupus erythematosus: evidence for inhibition of the function of activated plasma thromboplastin antecedent (factor XIa).
    Krieger H; Leddy JP; Breckenridge RT
    Blood; 1975 Aug; 46(2):189-97. PubMed ID: 237589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prekallikrein inhibition associated with the lupus anticoagulant: a mechanism of thrombosis.
    Sanfelippo MJ; Drayna CJ
    Am J Clin Pathol; 1982 Mar; 77(3):275-9. PubMed ID: 6803570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on some coagulation factors (Hageman factor, plasma prekallikrein, and high molecular weight kininogen) in the normal newborn.
    Gordon EM; Ratnoff OD; Saito H; Gross S; Jones PK
    Am J Pediatr Hematol Oncol; 1980; 2(3):213-6. PubMed ID: 7435882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formation of the fibrin clot: the balance of procoagulant and inhibitory factors.
    Lämmle B; Griffin JH
    Clin Haematol; 1985 Jun; 14(2):281-342. PubMed ID: 2994929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions among Hageman factor (HG, Factor XII), plasma thromboplastin antecedent (PTA, Factor XI), plasma prekallikrein (PK, Fletcher factor) and high molecular weight kininogen (HMW-K, Fitzgerald factor) in blood coagulation.
    Saito H; Ratnoff OD
    Adv Exp Med Biol; 1979; 120B():61-70. PubMed ID: 517254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysfibrinogenemia and lupus anticoagulant in a patient with recurrent thrombosis.
    Al-Mondhiry H; Galanakis D
    J Lab Clin Med; 1987 Dec; 110(6):726-33. PubMed ID: 3119749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on phospholipids in the action of a lupus coagulation inhibitor.
    Exner T; Rickard KA; Kronenberg H
    Pathology; 1975 Oct; 7(4):319-28. PubMed ID: 1223721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A unique precipitating autoantibody against plasma thromboplastin antecedent associated with multiple apparent plasma clotting factor deficiencies in a patient with systemic lupus erythematosus.
    Poon MC; Saito H; Koopman WJ
    Blood; 1984 Jun; 63(6):1309-17. PubMed ID: 6426550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiguanosine antibodies: a new marker for procainamide-induced systemic lupus erythematosus.
    Weisbart RH; Yee WS; Colburn KK; Whang SH; Heng MK; Boucek RJ
    Ann Intern Med; 1986 Mar; 104(3):310-3. PubMed ID: 3511820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lupus anticoagulant after measles.
    Muntean W; Petek W
    Eur J Pediatr; 1980 Aug; 134(2):135-8. PubMed ID: 6777164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII.
    Seligsohn U; Osterud B; Brown SF; Griffin JH; Rapaport SI
    J Clin Invest; 1979 Oct; 64(4):1056-65. PubMed ID: 479368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procainamide-induced lupus anticoagulant.
    Heyman MR; Flores RH; Edelman BB; Carliner NH
    South Med J; 1988 Jul; 81(7):934-6. PubMed ID: 3134699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombin generation assay as a possible tool for assessment of reduced activity of clotting factors induced by antiphospholipid antibodies and in-vitro evaluation of treatment options.
    Livnat T; Zivelin A; Tamarin I; Guetta V; Salomon O
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):661-6. PubMed ID: 19730246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demonstration of a platelet bypass mechanism in the clotting system using an acquired anticoagulant.
    Firkin BG; Booth P; Hendrix L; Howard MA
    Am J Hematol; 1978; 5(2):81-92. PubMed ID: 736036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolonged activated partial thromboplastin times.
    Alving BM; Barr CF; Tang DB
    Am J Med; 1990 Feb; 88(2):112-6. PubMed ID: 2105643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.